

# Taylor H Schreiber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6257326/publications.pdf>

Version: 2024-02-01

33  
papers

1,995  
citations

304743

22  
h-index

501196

28  
g-index

34  
all docs

34  
docs citations

34  
times ranked

3236  
citing authors

#	ARTICLE	IF	CITATIONS
1	CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity. <i>Cancer Immunology Research</i> , 2020, 8, 230-245.	3.4	30
2	Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy. , 2018, 6, 149.		35
3	Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. <i>Nature Biotechnology</i> , 2018, 36, 758-764.	17.5	201
4	Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors. <i>Gynecologic Oncology</i> , 2017, 145, 413-419.	1.4	19
5	Regulatory T Cell-Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9. <i>Journal of Immunology</i> , 2017, 199, 2721-2728.	0.8	60
6	Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination. <i>Cancer Immunology Research</i> , 2016, 4, 766-778.	3.4	19
7	Parallel Costimulation of Effector and Regulatory T Cells by OX40, GITR, TNFRSF25, CD27, and CD137: Implications for Cancer Immunotherapy. , 2016, , 59-78.		0
8	Disruption of polycystin-L causes hippocampal and thalamocortical hyperexcitability. <i>Human Molecular Genetics</i> , 2016, 25, 448-458.	2.9	24
9	Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents. <i>Journal of Immunotherapy</i> , 2015, 38, 259-266.	2.4	9
10	Immunological mechanisms of the antitumor effects of supplemental oxygenation. <i>Science Translational Medicine</i> , 2015, 7, 277ra30.	12.4	458
11	Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1 $\alpha$ -dependent and extracellular adenosine-mediated tumor protection. <i>Journal of Molecular Medicine</i> , 2014, 92, 1283-1292.	3.9	159
12	Heat-Shock Protein-Based Cancer Immunotherapy. , 2014, , 37-56.		0
13	The Role of B Cells in Shaping the Antitumor Immune Response. , 2014, , 19-35.		0
14	Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases. <i>Immunologic Research</i> , 2013, 57, 311-325.	2.9	33
15	Immunobiology of TNFSF15 and TNFRSF25. <i>Immunologic Research</i> , 2013, 57, 3-11.	2.9	35
16	B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 87-99.	4.2	75
17	Cloning, Expression, and Functional Characterization of TL1A-Ig. <i>Journal of Immunology</i> , 2013, 190, 1540-1550.	0.8	45
18	T Cell Costimulation by TNFR Superfamily (TNFRSF)4 and TNFRSF25 in the Context of Vaccination. <i>Journal of Immunology</i> , 2012, 189, 3311-3318.	0.8	29

#	ARTICLE	IF	CITATIONS
19	Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. <i>Oncolmunology</i> , 2012, 1, 642-648.	4.6	32
20	Tregs Expanded In Vivo by TNFRSF25 Agonists Promote Cardiac Allograft Survival. <i>Transplantation</i> , 2012, 94, 569-574.	1.0	48
21	TNFRSF25 Agonistic Antibody and Galectin-9 Combination Therapy Controls Herpes Simplex Virus-Induced Immunoinflammatory Lesions. <i>Journal of Virology</i> , 2012, 86, 10606-10620.	3.4	33
22	The Role of TNFRSF25:TNFSF15 in Disease and Health?. <i>Advances in Experimental Medicine and Biology</i> , 2011, 691, 289-298.	1.6	12
23	Response to Taraban, Ferdinand, and Al-Shamkhani. <i>Journal of Clinical Investigation</i> , 2011, 121, 465-465.	8.2	0
24	Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art. <i>Seminars in Immunology</i> , 2010, 22, 105-112.	5.6	44
25	Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. <i>Journal of Clinical Investigation</i> , 2010, 120, 3629-3640.	8.2	143
26	Tumor-Induced Suppression of CTL Expansion and Subjugation by gp96-Ig Vaccination. <i>Cancer Research</i> , 2009, 69, 2026-2033.	0.9	40
27	Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT. <i>Blood</i> , 2009, 113, 733-743.	1.4	46
28	Surmounting Tumor-induced Immune Suppression by Frequent Vaccination or Immunization in the Absence of B Cells. <i>Journal of Immunotherapy</i> , 2008, 31, 394-401.	2.4	36
29	The Use of FoxP3 as a Biomarker and Prognostic Factor for Malignant Human Tumors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1931-1934.	2.5	22
30	Shear flow-dependent integration of apical and subendothelial chemokines in T-cell transmigration: implications for locomotion and the multistep paradigm. <i>Blood</i> , 2007, 109, 1381-1386.	1.4	93
31	Surviving Host CD4+CD25+Foxp3+ Cells Following Ablative Conditioning Expand and Comprise the Major Component of the Treg Compartment during the Lymphoid Reconstitution Period Following HCT. <i>Blood</i> , 2007, 110, 65-65.	1.4	1
32	Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. <i>Regulatory Peptides</i> , 2004, 120, 5-13.	1.9	139
33	Identification and Characterization of a Novel Polycystin Family Member, Polycystin-L2, in Mouse and Human: Sequence, Expression, Alternative Splicing, and Chromosomal Localization. <i>Genomics</i> , 2000, 64, 241-251.	2.9	74